Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Neurol ; 15: 1342788, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38595850

RESUMO

Background: Uremic pruritus (UP) is a common complication of chronic kidney disease that causes sleep disturbances and increases all-cause mortality. Currently, the first-line medications for UP exhibit inadequate pruritus control with adverse effects. Various acupuncture point stimulation treatments (APSTs) have been shown to be effective as adjuvant therapies in UP, and a network meta-analysis can offer relative efficacy estimates for treatments for which head-to-head studies have not been performed. Methods: We conducted a random-effects network meta-analysis on a consistency model to compare the different APSTs for UP. The primary outcomes were the mean visual analog scale (VAS) score and effectiveness rate (ER). Results: The network meta-analysis retrieved 27 randomized controlled trials involving 1969 patients. Compared with conventional treatment alone, combination treatment with acupuncture (mean difference, -2.63; 95% confidence interval, -3.71 to -1.55) was the most effective intervention in decreasing VAS scores, followed by acupoint injection and massage (mean difference, -2.04; 95% confidence interval, -3.96 to -0.12). In terms of the ER, conventional treatment with acupuncture and hemoperfusion (risk ratio, 14.87; 95% confidence interval, 2.18 to 101.53) was superior to other therapeutic combinations. Considering the VAS score and ER, combination treatment with acupoint injection and massage showed benefits in treating UP. Conclusion: Our network meta-analysis provided relative efficacy data for choosing the optimal adjuvant treatment for UP. Combined treatment with acupuncture was more effective than conventional treatment only and was the most promising intervention for treating UP.Systematic review registration: PROSPERO (CRD42023425739: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023425739).

2.
Clin Exp Dermatol ; 2024 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-38320211

RESUMO

BACKGROUND: Erythema induratum (EI) is a tuberculid associated with Mycobacterium tuberculosis (TB) infection. TB has been identified in Taiwan with a high percentage of EI using PCR. However, this pathogen has rarely been detected recently. OBJECTIVE: To explore the association between EI, annual incidence of tuberculosis in Taiwan, and treatment outcomes over the past two decades. METHODS: Patients diagnosed with EI between 2001 and 2020 were enrolled based on histopathology, tissue culture, and TB-PCR tests. Other cases of panniculitis with TB-PCR results were used as controls. Their clinical information was obtained. The results were correlated with the annual incidence of tuberculosis and compared between groups. RESULTS: Fifty-five specimens from EI patients fulfilled the inclusion criteria; three (3/55, 5%) had positive TB PCR. One patient diagnosed with erythema nodosum in the control group had positive TB PCR (1/27, 4%). There was no significant relationship between TB and EI (odds ratio = 1.5, 95% confidence interval = -0.964 to 3.964, p = 1). Correlation between the incidence of TB and number of EI cases was not significant (r = -0.185, p = 0.447). Only four patients received anti-tuberculosis therapy. They all showed clinical improvement without recurrence. One patient with PCR-positive EI was not treated with anti-tuberculosis therapy; however, the skin lesion improved 3 months later. No other patients in the EI group were diagnosed with TB infection in the follow up of 508 person-years. CONCLUSIONS: Most EI in Taiwan are nodular vasculitis and not tuberculids owing to well-controlled tuberculosis. This condition can be alleviated without anti-tuberculosis therapy.

3.
Front Med (Lausanne) ; 9: 1036072, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36530891

RESUMO

Background: Uremic pruritus causes sleep disturbances, poor quality of life, and increased morbidity in patients with chronic kidney disease. Acupuncture has been shown to improve uremic pruritus. There is limited evidence of the efficacy of traditional Chinese therapies. We conducted a systematic review and meta-analysis to evaluate the efficacy of acupoint stimulation therapy in patients with uremic pruritus. Methods: A systematic search of seven databases (up to Sep 2022) was conducted for randomized controlled trials that evaluated the clinical efficacy of acupuncture, acupressure, auricular acupressure, acupoint injection, acupoint thermal therapy, acupoint sticking therapy, or transcutaneous electrical acupoint stimulation in the treatment of patients with uremic pruritus. Two reviewers selected eligible articles for inclusion in the meta-analysis and evaluated the risk of bias via Cochrane Collaboration. The results of pruritus assessments and uremic pruritus-related laboratory parameters were analyzed. Results: Forty trials published between 2002 and 2022, including a total of 2,735 participants, were identified for inclusion in the meta-analysis. The effective rates for acupuncture, auricular acupressure, and the combination of acupoint injection and acupoint massage were significantly greater in patients with uremic pruritus compared to the control group. The levels of serum BUN, PTH, and histamine levels were significantly lower vs. control group. Conclusions: Acupuncture, auricular acupressure, and the combination of acupoint injection and acupoint massage seem to be effective in improving uremic pruritus in patients with chronic kidney disease. However, further investigation of these potential treatments is now warranted in larger patient populations and over a longer time frame. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022354585, identifier: PROSPERO CRD42022354585.

4.
Toxins (Basel) ; 13(11)2021 10 30.
Artigo em Inglês | MEDLINE | ID: mdl-34822553

RESUMO

Uremic pruritus is a distressful complication of chronic kidney disease and results in impaired quality of life and higher mortality rates. Intravenous sodium thiosulfate has been reported to alleviate pruritus in hemodialysis patients. We performed a systematic review and meta-analysis to estimate the efficacy of intravenous sodium thiosulfate in patients with uremic pruritus. A systematic search of electronic databases up to June 2021 was conducted for randomized controlled trials that evaluated the clinical effects of sodium thiosulfate in the management of patients with uremic pruritus. Two reviewers selected eligible articles and evaluated the risk of bias; the results of pruritus assessment and uremic pruritus-related laboratory parameters in selected studies were analyzed. There are four trials published between 2018 and 2021, which include 222 participants. The sodium thiosulfate group displayed significant decrease in the pruritus score (standardized mean difference = -3.52, 95% confidence interval = -5.63 to -1.41, p = 0.001), without a significant increase in the adverse effects (risk ratio = 2.44, 95% confidence interval = 0.37 to 15.99, p = 0.35) compared to the control group. Administration of sodium thiosulfate is found to be a safe and efficacious complementary therapy in improving uremic pruritus in patients with chronic kidney disease.


Assuntos
Antioxidantes/efeitos adversos , Prurido/tratamento farmacológico , Tiossulfatos/efeitos adversos , Uremia/tratamento farmacológico , Vasodilatadores/efeitos adversos , Antioxidantes/farmacologia , Humanos , Prurido/etiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Tiossulfatos/farmacologia , Uremia/complicações , Vasodilatadores/farmacologia
5.
Toxins (Basel) ; 13(10)2021 10 04.
Artigo em Inglês | MEDLINE | ID: mdl-34678995

RESUMO

Uremic pruritus is common among patients with advanced or end-stage renal disease, with an incidence of >40% among patients on dialysis. Uremic clearance granules (UCGs) are effective in managing uremic pruritus and delay the progression of chronic kidney disease. We conducted a systematic review and a meta-analysis to evaluate the efficacy of UCG in patients with uremic pruritus. Several electronic databases were searched systematically from their inceptions until 19 July 2021. Randomized control trials evaluating the efficacy of UCG in patients with uremic pruritus were selected. Eleven trials including 894 participants were published between 2011 and 2021. Patients administered UCGs had a significantly decreased visual analog scale score (mean difference [MD], -2.02; 95% confidence interval [CI], -2.17 to -1.88), serum levels of hsCRP (MD, -2.07 mg/dL; 95% CI, -2.89 to -1.25; p < 0.00001), TNF-α (MD, -15.23 mg/L; 95% CI, -20.00 to -10.47; p < 0.00001]), ß2-MG (MD, -10.18 mg/L; 95% CI, -15.43 to -4.93; p < 0.00001), and IL-6 (MD, -6.13 mg/L; 95% CI, -7.42 to -4.84; p < 0.00001). In addition, UCGs significantly reduced serum levels of creatinine, BUN, PTH, iPTH, phosphorus, and the overall effectiveness rate. UCGs could be an attractive complementary therapy for patients with uremic pruritus.


Assuntos
Prurido/metabolismo , Insuficiência Renal Crônica/prevenção & controle , Uremia/metabolismo , Humanos , Prurido/sangue , Insuficiência Renal Crônica/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...